Rallybio Corp (RLYB) stock
RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.47−0.05 (-0.32%)
Close on Nov 20, 2026Market cap $83.29MP/E 3.4Yield –
Rallybio net income
Net income is the profit left for shareholders after every expense, interest and tax.
Rallybio's net income for the twelve months ending Sep 30, 2026 was $26.81M. For fiscal 2025 it was -$8.98M. The highest annual figure on record is -$8.98M in fiscal 2025.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$8.98M | – |
| FY2024 | Dec 31, 2024 | -$57.78M | – |
| FY2023 | Dec 31, 2023 | -$74.56M | – |
| FY2022 | Dec 31, 2022 | -$66.65M | – |
| FY2021 | Dec 31, 2021 | -$47.01M | – |
| FY2020 | Dec 31, 2020 | -$26.45M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$2.73M | -117.0% |
| Q2 FY2026 | Jun 30, 2026 | $43.67M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.28M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.85M | – |
| Q3 FY2025 | Sep 30, 2025 | $16.02M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.70M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.44M | – |
| Q4 FY2024 | Dec 31, 2024 | -$11.04M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.47M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.24M | – |
| Q1 FY2024 | Mar 31, 2024 | -$19.03M | – |
| Q4 FY2023 | Dec 31, 2023 | -$20.24M | – |
| Q3 FY2023 | Sep 30, 2023 | -$18.37M | – |
| Q2 FY2023 | Jun 30, 2023 | -$18.63M | – |
| Q1 FY2023 | Mar 31, 2023 | -$17.32M | – |
| Q4 FY2022 | Dec 31, 2022 | -$16.20M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.37M | – |
| Q2 FY2022 | Jun 30, 2022 | -$17.58M | – |
| Q1 FY2022 | Mar 31, 2022 | -$14.50M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.42M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.20M | – |
| Q2 FY2021 | Jun 30, 2021 | -$11.13M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.28M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.52M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.16M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.89M | – |
See a number that looks wrong?